Qingxiang Yan
Qingxiang Yan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Adam T. Boutin
6 shared publications- Ayumu Taguchi
Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
6 shared publications Dean E. Brenner
6 shared publications- Melanie Haas Kucherlapati
Department of Genetics, Harvard Medical School, Boston, MA, USA
6 shared publications - Paul D. Lampe
Fred Hutchinson Cancer Center
6 shared publications - Raju Kucherlapati
Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women’s Hospital, Boston, MA, USA
6 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
- 2 February 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (9) , 1398-1411
Conditional concordance‐assisted learning under matched case‐control design for combining biomarkers for population screening
Incorporating promising biomarkers into cancer screening practices for early-detection is increasingly appealing because of the unsatisfactory performance of current cancer screening strategies. The matched case-control design is commonly adopted in biomarker development studies to evaluate the discriminative power of biomarker candidates, with an intention to eliminate confounding effects. Data from matched case-control studies have been routinely analyzed by the conditional logistic regression, although the assumed logit link between biomarker combinations and disease risk may not always hold. We propose a conditional concordance-assisted learning method, which is distribution-free, for identifying an optimal combination of biomarkers to discriminate cases and controls. We are particularly interested in combinations with a clinically and practically meaningful specificity to prevent disease-free subjects from unnecessary and possibly intrusive diagnostic procedures, which is a top priority for cancer population screening. We establish asymptotic properties for the derived combination and confirm its favorable finite sample performance in simulations. We apply the proposed method to the prostate cancer data from the carotene and retinol efficacy trial (CARET).
- 2 February 2023
- Published by Wiley in Statistics in Medicine
- Vol. 42 (9) , 1398-1411
Conditional concordance‐assisted learning under matched case‐control design for combining biomarkers for population screening
Incorporating promising biomarkers into cancer screening practices for early-detection is increasingly appealing because of the unsatisfactory performance of current cancer screening strategies. The matched case-control design is commonly adopted in biomarker development studies to evaluate the discriminative power of biomarker candidates, with an intention to eliminate confounding effects. Data from matched case-control studies have been routinely analyzed by the conditional logistic regression, although the assumed logit link between biomarker combinations and disease risk may not always hold. We propose a conditional concordance-assisted learning method, which is distribution-free, for identifying an optimal combination of biomarkers to discriminate cases and controls. We are particularly interested in combinations with a clinically and practically meaningful specificity to prevent disease-free subjects from unnecessary and possibly intrusive diagnostic procedures, which is a top priority for cancer population screening. We establish asymptotic properties for the derived combination and confirm its favorable finite sample performance in simulations. We apply the proposed method to the prostate cancer data from the carotene and retinol efficacy trial (CARET).
- 30 October 2017
- Published by Wiley in Statistics in Medicine
- Vol. 37 (4) , 627-642
Combining multiple biomarkers linearly to maximize the partial area under the ROC curve
It is now common in clinical practice to make clinical decisions based on combinations of multiple biomarkers. In this paper, we propose new approaches for combining multiple biomarkers linearly to maximize the partial area under the receiver operating characteristic curve (pAUC). The parametric and nonparametric methods that have been developed for this purpose have limitations. When the biomarker values for populations with and without a given disease follow a multivariate normal distribution, it is easy to implement our proposed parametric approach, which adopts an alternative analytic expression of the pAUC. When normality assumptions are violated, a kernel‐based approach is presented, which handles multiple biomarkers simultaneously. We evaluated the proposed as well as existing methods through simulations and discovered that when the covariance matrices for the disease and nondisease samples are disproportional, traditional methods (such as the logistic regression) are more likely to fail to maximize the pAUC while the proposed methods are more robust. The proposed approaches are illustrated through application to a prostate cancer data set, and a rank‐based leave‐one‐out cross‐validation procedure is proposed to obtain a realistic estimate of the pAUC when there is no independent validation set available.
- 30 October 2017
- Published by Wiley in Statistics in Medicine
- Vol. 37 (4) , 627-642
Combining multiple biomarkers linearly to maximize the partial area under the ROC curve
It is now common in clinical practice to make clinical decisions based on combinations of multiple biomarkers. In this paper, we propose new approaches for combining multiple biomarkers linearly to maximize the partial area under the receiver operating characteristic curve (pAUC). The parametric and nonparametric methods that have been developed for this purpose have limitations. When the biomarker values for populations with and without a given disease follow a multivariate normal distribution, it is easy to implement our proposed parametric approach, which adopts an alternative analytic expression of the pAUC. When normality assumptions are violated, a kernel‐based approach is presented, which handles multiple biomarkers simultaneously. We evaluated the proposed as well as existing methods through simulations and discovered that when the covariance matrices for the disease and nondisease samples are disproportional, traditional methods (such as the logistic regression) are more likely to fail to maximize the pAUC while the proposed methods are more robust. The proposed approaches are illustrated through application to a prostate cancer data set, and a rank‐based leave‐one‐out cross‐validation procedure is proposed to obtain a realistic estimate of the pAUC when there is no independent validation set available.
- 7 August 2017
- Published by Wiley in Statistics in Medicine
- Vol. 36 (24) , 3830-3843
Estimation of smooth ROC curves for biomarkers with limits of detection
Protein biomarkers found in plasma are commonly used for cancer screening and early detection. Measurements obtained by such markers are often based on different assays that may not support detection of accurate measurements due to a limit of detection. TheROCcurve is the most popular statistical tool for the evaluation of a continuous biomarker. However, in situations where limits of detection exist, the empiricalROCcurve fails to provide a valid estimate for the whole spectrum of the false positive rate (FPR). Hence, crucial information regarding the performance of the marker in high sensitivity and/or high specificity values is not revealed. In this paper, we address this problem and propose methods for constructingROCcurve estimates for all possibleFPRvalues. We explore flexible parametric methods, transformations to normality, and robust kernel‐based and spline‐based approaches. We evaluate our methods though simulations and illustrate them in colorectal and pancreatic cancer data.
- 7 August 2017
- Published by Wiley in Statistics in Medicine
- Vol. 36 (24) , 3830-3843
Estimation of smooth ROC curves for biomarkers with limits of detection
Protein biomarkers found in plasma are commonly used for cancer screening and early detection. Measurements obtained by such markers are often based on different assays that may not support detection of accurate measurements due to a limit of detection. TheROCcurve is the most popular statistical tool for the evaluation of a continuous biomarker. However, in situations where limits of detection exist, the empiricalROCcurve fails to provide a valid estimate for the whole spectrum of the false positive rate (FPR). Hence, crucial information regarding the performance of the marker in high sensitivity and/or high specificity values is not revealed. In this paper, we address this problem and propose methods for constructingROCcurve estimates for all possibleFPRvalues. We explore flexible parametric methods, transformations to normality, and robust kernel‐based and spline‐based approaches. We evaluate our methods though simulations and illustrate them in colorectal and pancreatic cancer data.
- Open Access
- 1 November 2015
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 8 (11) , 1112-1119
MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
Blood-based biomarkers for early detection of colorectal cancer could complement current approaches to colorectal cancer screening. We previously identified the APC-binding protein MAPRE1 as a potential colorectal cancer biomarker. Here, we undertook a case–control validation study to determine the performance of MAPRE1 in detecting early colorectal cancer and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early colorectal cancer, 30 with advanced colorectal cancer, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and carcinoembryonic antigen (CEA) was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in colorectal cancer mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with colorectal cancer compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early colorectal cancer from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early colorectal cancer patient plasma samples and in plasma from colorectal cancer mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early colorectal cancer, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage colorectal cancer and adenomas together with other biomarkers. Cancer Prev Res; 8(11); 1112–9. ©2015 AACR.
- 1 November 2015
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 8 (11) , 1112-1119
Open AccessMAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas
Blood-based biomarkers for early detection of colorectal cancer could complement current approaches to colorectal cancer screening. We previously identified the APC-binding protein MAPRE1 as a potential colorectal cancer biomarker. Here, we undertook a case–control validation study to determine the performance of MAPRE1 in detecting early colorectal cancer and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early colorectal cancer, 30 with advanced colorectal cancer, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and carcinoembryonic antigen (CEA) was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in colorectal cancer mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with colorectal cancer compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early colorectal cancer from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early colorectal cancer patient plasma samples and in plasma from colorectal cancer mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early colorectal cancer, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage colorectal cancer and adenomas together with other biomarkers. Cancer Prev Res; 8(11); 1112–9. ©2015 AACR.